Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies

CD20 is a nonglycosylated 33 to 37 kD phosphoprotein involved in B-cell signaling that subserves important functions in the regulation of B-cell proliferation and differentiation. In addition, this B-cell surface antigen has been shown recently to be an effective target for immunotherapy of B-cell m...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 1998-03, Vol.91 (5), p.1644-1652
Hauptverfasser: DAMING SHAN, LEDBETTER, J. A, PRESS, O. W
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1652
container_issue 5
container_start_page 1644
container_title Blood
container_volume 91
creator DAMING SHAN
LEDBETTER, J. A
PRESS, O. W
description CD20 is a nonglycosylated 33 to 37 kD phosphoprotein involved in B-cell signaling that subserves important functions in the regulation of B-cell proliferation and differentiation. In addition, this B-cell surface antigen has been shown recently to be an effective target for immunotherapy of B-cell malignancies using chimeric (mouse/human) or radiolabeled murine monoclonal anti-CD20 antibodies. In this report we show that extensive crosslinking of CD20 with murine anti-CD20 monoclonal antibodies (MoAbs) in the presence of either goat anti-mouse IgG or Fc receptor (FcR)-expressing cells directly inhibits B-cell proliferation, induces nuclear DNA fragmentation, and leads to cell death by apoptosis. The apoptotic effects of these MoAbs can be inhibited by chelation of extracellular or intracellular Ca2+ by EGTA or Bapta AM, indicating that anti-CD20-mediated apoptosis may be related to changes in Ca2+ concentration. These findings suggest that ligation of CD20 in vivo by anti-CD20 antibodies in the presence of FcR-expressing cells may initiate signal transduction events that induce elevation of [Ca2+]i and lead to apoptosis of malignant B cells, thereby contributing to the impressive tumor regressions observed in mouse models and clinical trials using anti-CD20 MoAbs.
doi_str_mv 10.1182/blood.v91.5.1644
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79702503</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79702503</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2804-40f1841b661d60df7a07fdd63f29bd11e16ecf9169e5313f7c5e55141bc39f013</originalsourceid><addsrcrecordid>eNo9kDtPwzAUhS0EgvLYWZA8ILaUe-3YrkcoTwmJgcdqOY4NRklc4hTEvyeFqtMdzvcdXR1CjhGmiDN2XjUp1dMvjVMxRVmWW2SCgs0KAAbbZAIAsii1wj2yn_MHAJaciV2yq0vFGYcJebpYpMWQcsw0BdraJr51thvo-7K1Hb2kzjdNptUPHQM7xNStsPkVA_odh3fapi65JnW2oaMVq1RHnw_JTrBN9kfre0Bebq6f53fFw-Pt_fzioXBsBmVRQsBZiZWUWEuog7KgQl1LHpiuakSP0rugUWovOPKgnPBC4Gg4rgMgPyBn_72LPn0ufR5MG_PqYdv5tMxGaQVMAB9B-Addn3LufTCLPra2_zEIZrWj-dvRvGo0wqx2HJWTdfeyan29EdbDjfnpOrfZ2Sb0tnMxbzCGSklU_BfI9ntM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79702503</pqid></control><display><type>article</type><title>Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>DAMING SHAN ; LEDBETTER, J. A ; PRESS, O. W</creator><creatorcontrib>DAMING SHAN ; LEDBETTER, J. A ; PRESS, O. W</creatorcontrib><description>CD20 is a nonglycosylated 33 to 37 kD phosphoprotein involved in B-cell signaling that subserves important functions in the regulation of B-cell proliferation and differentiation. In addition, this B-cell surface antigen has been shown recently to be an effective target for immunotherapy of B-cell malignancies using chimeric (mouse/human) or radiolabeled murine monoclonal anti-CD20 antibodies. In this report we show that extensive crosslinking of CD20 with murine anti-CD20 monoclonal antibodies (MoAbs) in the presence of either goat anti-mouse IgG or Fc receptor (FcR)-expressing cells directly inhibits B-cell proliferation, induces nuclear DNA fragmentation, and leads to cell death by apoptosis. The apoptotic effects of these MoAbs can be inhibited by chelation of extracellular or intracellular Ca2+ by EGTA or Bapta AM, indicating that anti-CD20-mediated apoptosis may be related to changes in Ca2+ concentration. These findings suggest that ligation of CD20 in vivo by anti-CD20 antibodies in the presence of FcR-expressing cells may initiate signal transduction events that induce elevation of [Ca2+]i and lead to apoptosis of malignant B cells, thereby contributing to the impressive tumor regressions observed in mouse models and clinical trials using anti-CD20 MoAbs.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood.v91.5.1644</identifier><identifier>PMID: 9473230</identifier><language>eng</language><publisher>Washington, DC: The Americain Society of Hematology</publisher><subject>Animals ; Antibodies, Anti-Idiotypic - pharmacology ; Antibodies, Monoclonal - pharmacology ; Antigens, CD20 - immunology ; Antigens, CD20 - physiology ; Antineoplastic agents ; Apoptosis ; B-Lymphocytes - immunology ; B-Lymphocytes - physiology ; Biological and medical sciences ; Burkitt Lymphoma - pathology ; Calcium - metabolism ; Cell Cycle ; Cell Division ; Chelating Agents - pharmacology ; Cross-Linking Reagents ; Egtazic Acid - analogs &amp; derivatives ; Egtazic Acid - pharmacology ; Goats ; Humans ; Immunotherapy ; Medical sciences ; Mice ; Pharmacology. Drug treatments ; Receptors, Fc - physiology ; Tumor Cells, Cultured</subject><ispartof>Blood, 1998-03, Vol.91 (5), p.1644-1652</ispartof><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2804-40f1841b661d60df7a07fdd63f29bd11e16ecf9169e5313f7c5e55141bc39f013</citedby><cites>FETCH-LOGICAL-c2804-40f1841b661d60df7a07fdd63f29bd11e16ecf9169e5313f7c5e55141bc39f013</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2177617$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9473230$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DAMING SHAN</creatorcontrib><creatorcontrib>LEDBETTER, J. A</creatorcontrib><creatorcontrib>PRESS, O. W</creatorcontrib><title>Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies</title><title>Blood</title><addtitle>Blood</addtitle><description>CD20 is a nonglycosylated 33 to 37 kD phosphoprotein involved in B-cell signaling that subserves important functions in the regulation of B-cell proliferation and differentiation. In addition, this B-cell surface antigen has been shown recently to be an effective target for immunotherapy of B-cell malignancies using chimeric (mouse/human) or radiolabeled murine monoclonal anti-CD20 antibodies. In this report we show that extensive crosslinking of CD20 with murine anti-CD20 monoclonal antibodies (MoAbs) in the presence of either goat anti-mouse IgG or Fc receptor (FcR)-expressing cells directly inhibits B-cell proliferation, induces nuclear DNA fragmentation, and leads to cell death by apoptosis. The apoptotic effects of these MoAbs can be inhibited by chelation of extracellular or intracellular Ca2+ by EGTA or Bapta AM, indicating that anti-CD20-mediated apoptosis may be related to changes in Ca2+ concentration. These findings suggest that ligation of CD20 in vivo by anti-CD20 antibodies in the presence of FcR-expressing cells may initiate signal transduction events that induce elevation of [Ca2+]i and lead to apoptosis of malignant B cells, thereby contributing to the impressive tumor regressions observed in mouse models and clinical trials using anti-CD20 MoAbs.</description><subject>Animals</subject><subject>Antibodies, Anti-Idiotypic - pharmacology</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antigens, CD20 - immunology</subject><subject>Antigens, CD20 - physiology</subject><subject>Antineoplastic agents</subject><subject>Apoptosis</subject><subject>B-Lymphocytes - immunology</subject><subject>B-Lymphocytes - physiology</subject><subject>Biological and medical sciences</subject><subject>Burkitt Lymphoma - pathology</subject><subject>Calcium - metabolism</subject><subject>Cell Cycle</subject><subject>Cell Division</subject><subject>Chelating Agents - pharmacology</subject><subject>Cross-Linking Reagents</subject><subject>Egtazic Acid - analogs &amp; derivatives</subject><subject>Egtazic Acid - pharmacology</subject><subject>Goats</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Pharmacology. Drug treatments</subject><subject>Receptors, Fc - physiology</subject><subject>Tumor Cells, Cultured</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kDtPwzAUhS0EgvLYWZA8ILaUe-3YrkcoTwmJgcdqOY4NRklc4hTEvyeFqtMdzvcdXR1CjhGmiDN2XjUp1dMvjVMxRVmWW2SCgs0KAAbbZAIAsii1wj2yn_MHAJaciV2yq0vFGYcJebpYpMWQcsw0BdraJr51thvo-7K1Hb2kzjdNptUPHQM7xNStsPkVA_odh3fapi65JnW2oaMVq1RHnw_JTrBN9kfre0Bebq6f53fFw-Pt_fzioXBsBmVRQsBZiZWUWEuog7KgQl1LHpiuakSP0rugUWovOPKgnPBC4Gg4rgMgPyBn_72LPn0ufR5MG_PqYdv5tMxGaQVMAB9B-Addn3LufTCLPra2_zEIZrWj-dvRvGo0wqx2HJWTdfeyan29EdbDjfnpOrfZ2Sb0tnMxbzCGSklU_BfI9ntM</recordid><startdate>19980301</startdate><enddate>19980301</enddate><creator>DAMING SHAN</creator><creator>LEDBETTER, J. A</creator><creator>PRESS, O. W</creator><general>The Americain Society of Hematology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19980301</creationdate><title>Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies</title><author>DAMING SHAN ; LEDBETTER, J. A ; PRESS, O. W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2804-40f1841b661d60df7a07fdd63f29bd11e16ecf9169e5313f7c5e55141bc39f013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Animals</topic><topic>Antibodies, Anti-Idiotypic - pharmacology</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antigens, CD20 - immunology</topic><topic>Antigens, CD20 - physiology</topic><topic>Antineoplastic agents</topic><topic>Apoptosis</topic><topic>B-Lymphocytes - immunology</topic><topic>B-Lymphocytes - physiology</topic><topic>Biological and medical sciences</topic><topic>Burkitt Lymphoma - pathology</topic><topic>Calcium - metabolism</topic><topic>Cell Cycle</topic><topic>Cell Division</topic><topic>Chelating Agents - pharmacology</topic><topic>Cross-Linking Reagents</topic><topic>Egtazic Acid - analogs &amp; derivatives</topic><topic>Egtazic Acid - pharmacology</topic><topic>Goats</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Pharmacology. Drug treatments</topic><topic>Receptors, Fc - physiology</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DAMING SHAN</creatorcontrib><creatorcontrib>LEDBETTER, J. A</creatorcontrib><creatorcontrib>PRESS, O. W</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DAMING SHAN</au><au>LEDBETTER, J. A</au><au>PRESS, O. W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>1998-03-01</date><risdate>1998</risdate><volume>91</volume><issue>5</issue><spage>1644</spage><epage>1652</epage><pages>1644-1652</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>CD20 is a nonglycosylated 33 to 37 kD phosphoprotein involved in B-cell signaling that subserves important functions in the regulation of B-cell proliferation and differentiation. In addition, this B-cell surface antigen has been shown recently to be an effective target for immunotherapy of B-cell malignancies using chimeric (mouse/human) or radiolabeled murine monoclonal anti-CD20 antibodies. In this report we show that extensive crosslinking of CD20 with murine anti-CD20 monoclonal antibodies (MoAbs) in the presence of either goat anti-mouse IgG or Fc receptor (FcR)-expressing cells directly inhibits B-cell proliferation, induces nuclear DNA fragmentation, and leads to cell death by apoptosis. The apoptotic effects of these MoAbs can be inhibited by chelation of extracellular or intracellular Ca2+ by EGTA or Bapta AM, indicating that anti-CD20-mediated apoptosis may be related to changes in Ca2+ concentration. These findings suggest that ligation of CD20 in vivo by anti-CD20 antibodies in the presence of FcR-expressing cells may initiate signal transduction events that induce elevation of [Ca2+]i and lead to apoptosis of malignant B cells, thereby contributing to the impressive tumor regressions observed in mouse models and clinical trials using anti-CD20 MoAbs.</abstract><cop>Washington, DC</cop><pub>The Americain Society of Hematology</pub><pmid>9473230</pmid><doi>10.1182/blood.v91.5.1644</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 1998-03, Vol.91 (5), p.1644-1652
issn 0006-4971
1528-0020
language eng
recordid cdi_proquest_miscellaneous_79702503
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Animals
Antibodies, Anti-Idiotypic - pharmacology
Antibodies, Monoclonal - pharmacology
Antigens, CD20 - immunology
Antigens, CD20 - physiology
Antineoplastic agents
Apoptosis
B-Lymphocytes - immunology
B-Lymphocytes - physiology
Biological and medical sciences
Burkitt Lymphoma - pathology
Calcium - metabolism
Cell Cycle
Cell Division
Chelating Agents - pharmacology
Cross-Linking Reagents
Egtazic Acid - analogs & derivatives
Egtazic Acid - pharmacology
Goats
Humans
Immunotherapy
Medical sciences
Mice
Pharmacology. Drug treatments
Receptors, Fc - physiology
Tumor Cells, Cultured
title Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T09%3A17%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Apoptosis%20of%20malignant%20human%20B%20cells%20by%20ligation%20of%20CD20%20with%20monoclonal%20antibodies&rft.jtitle=Blood&rft.au=DAMING%20SHAN&rft.date=1998-03-01&rft.volume=91&rft.issue=5&rft.spage=1644&rft.epage=1652&rft.pages=1644-1652&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood.v91.5.1644&rft_dat=%3Cproquest_cross%3E79702503%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79702503&rft_id=info:pmid/9473230&rfr_iscdi=true